Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1/2 dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics and preliminary efficacy of DTX-SPL8783 (a docetaxel (DTX)-dendrimer conjugate) as monotherapy in patients with advanced solid tumours or in combination with nintedanib in patients with non-small cell lung cancer (NSCLC)

Trial Profile

A phase 1/2 dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics and preliminary efficacy of DTX-SPL8783 (a docetaxel (DTX)-dendrimer conjugate) as monotherapy in patients with advanced solid tumours or in combination with nintedanib in patients with non-small cell lung cancer (NSCLC)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Docetaxel (Primary) ; Nintedanib
  • Indications Adenocarcinoma; Lung cancer; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
  • Sponsors Starpharma
  • Most Recent Events

    • 24 Aug 2023 According to a Starpharma media release, 50 patients were recruited and treated with DEP docetaxel in the monotherapy arm and Phase 2 results are expected in Q3 CY23, with partnering discussions ongoing.
    • 27 Feb 2019 Interim results published in the Starpharma Financial Media Release
    • 27 Feb 2019 According to a Starpharma media release, new sites opened to support recruitment (four sites in total). Patient enrollment has been completed in the first cohort of patients with lung cancer in the combination study of DEP docetaxel + nintedanib (Vargatef) and recruitment has been expanded in non-small cell lung cancer based on positive interim results. In the monotherapy arm, approximately 70% of patients in the initial cohort have been recruited.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top